Updated Review on Treatment of Atopic Dermatitis

Instructions for obtaining 1.2 Continuing Medical Education Credits

Credits can be earned by reading the text and completing the CME examinations online throughout the year on the SEAIC web site at www.seaic.org

"Actividad acreditada por el Consejo Catalán de Formación Continuada de las Profesiones Sanitarias – Comisión de Formación Continuada del Sistema Nacional de Salud con 1,2 CRÉITOS".

Activity sponsored by Astra Laboratories

AstraZeneca takes no responsibility for the contents of this program
CME Items

1. Which of the following statements about atopic dermatitis is correct?
   a. Atopic dermatitis alters the barrier function and dysfunction of the immune system towards a TH12 response.
   b. Atopic dermatitis is currently considered a model of imbalance between TH1 and TH2 inflammatory responses.
   c. Atopic dermatitis is a homogeneous disease involving environmental agents capable of triggering the disease in individuals with genetic susceptibility.
   d. All of the above.

2. Which of the following are objectives of treatment in atopic dermatitis?
   a. To maintain the barrier function of the skin.
   b. To alleviate pruritus.
   c. To avoid superinfections.
   d. All of the above.

3. Of the following drugs, select a topical inhibitor of phosphodiesterase-4.
   a. Tacrolimus.
   b. Pimecrolimus.
   c. Tapinarof.
   d. Lotamilast.

4. With respect to ominagan, which of the following sentences is false?
   a. It is an antimicrobial peptide gel.
   b. We have data from a phase 3 randomized trial.
   c. Ominagan has shown significant but small differences in BSA, SCORAD, and pruritus.
   d. Ominagan gel was given once daily for 4 weeks.

5. Which of the following clinical trials evaluates the efficacy and safety of upadacitinib?
   b. BREEZE AD.
   c. AD MONO.
   d. None of the above.

6. Which of the following was the most common adverse event shown in safety data from upadacitinib?
   a. Acne.
   b. Nausea.
   c. Upper respiratory tract infections.
   d. Herpes simplex.

7. Which of the following drugs is a dual inhibitor of the JAK and SYK pathways?
   a. Abrocitinib.
   b. Gusacitinib.
   c. Upadacitinib.
   d. Baricitinib.

8. Choose the correct sentence.
   a. Dupilumab is authorized in by the United States Food and Drug Administration for treatment of moderate-to-severe atopic dermatitis in adults but is not approved in the European Union.
   b. LIBERTY AD SOLO evaluated the efficacy and safety of dupilumab, demonstrating that dupilumab was not superior to placebo.
   c. Some authors recommend using artificial tears when starting treatment with dupilumab, which can cause conjunctivitis, although the percentage affected is reported to be <10%.
   d. No real-world evidence studies have been conducted on dupilumab.

9. Which association between the biological drug and therapeutic target is not correct?
   b. Lebrikizumab and IL-13.
   c. Tralokinumab and IL-12.
   d. Dupilumab and IL-4.

10. Select the clinical trial that has demonstrated superiority of tralokinumab over placebo in atopic dermatitis.
    a. ECZTRA.
    b. LIBERTY.
    c. ARCADIA.
    d. ADVOCATE.